Successful outcome using rituximab as the only immunomodulation in Henoch-Schonlein purpura: case report.

In the current report, we describe a patient with moderate nephritis and severe skin Henoch Schönlein purpura (HSP) who has been treated with rituximab. Complete and sustained skin and renal remission resulted from the treatment. Thus, further studies are required to confirm the efficacy of rituximab as first-line treatment in HSP, and it might be an interesting new therapeutic option.

[1]  E. Thervet,et al.  Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura. , 2010, Kidney international.

[2]  J. Novak,et al.  Pathogenesis of Henoch-Schönlein purpura nephritis , 2009, Pediatric nephrology (Berlin, West).

[3]  M. Zaffanello,et al.  Treatment-based literature of Henoch–Schönlein purpura nephritis in childhood , 2009, Pediatric Nephrology.

[4]  M. Levesque.  Translational Mini‐Review Series on B Cell‐Directed Therapies: Recent advances in B cell‐directed biological therapies for autoimmune disorders , 2009, Clinical and experimental immunology.

[5]  R. Cron,et al.  Rituximab therapy for severe refractory chronic Henoch-Schönlein purpura. , 2009, The Journal of pediatrics.

[6]  J. Craig,et al.  Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP). , 2009, The Cochrane database of systematic reviews.

[7]  Chris Feudtner,et al.  Effects of Corticosteroid on Henoch-Schönlein Purpura: A Systematic Review , 2007, Pediatrics.

[8]  F. Saulsbury.  Clinical update: Henoch-Schönlein purpura , 2007, The Lancet.

[9]  M. Nuutinen,et al.  The adult kidney 24 years after childhood Henoch-Schönlein purpura: a retrospective cohort study , 2002, The Lancet.

[10]  E. Thervet,et al.  Henoch-Schönlein Purpura in adults: outcome and prognostic factors. , 2002, Journal of the American Society of Nephrology : JASN.